Fig 1: FLZ administration attenuates BBB impairment caused by rotenone. (A) Representative electron micrographs showing the tight junction structure of BBB. (B) Representative captures of immunofluorescence of ZO-1 in the SN. (C) The intensity analysis of ZO-1 immunofluorescence staining. (D) Representative Western blot brands of ZO-1, occludin and claudin-5 in SN. (E)–(G) The density analysis results of ZO-1, occludin and claudin-5 Western blot in SN. (H)–(J) mRNA expression of tight junction proteins Zo1, Ocln and Cldn5. (K) Levels of LPS endotoxin in the SN. In (C), n = 5 for each group. In (E)–(G), n = 4 for each group. In (H)–(J), n = 3 for each group. In (K), n = 8 for each group. Data are presented as mean ± SD. #P < 0.05, ##P < 0.01, ###P < 0.001 versus the Control group; **P < 0.01, ***P < 0.001 versus the Rotenone group.